# A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease

> **NCT03136991** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 38 (actual)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** AZD4831
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03136991
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-15
- **Primary completion:** 2017-11-22
- **Final completion:** 2017-11-22
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03136991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03136991, "A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03136991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*